small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 81 results

Industry

Medical Devices

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions....Read more

Industry

Financial Crimes Compliance

Winston’s financial crimes compliance lawyers have been providing regulatory compliance counseling and enforcement services related to the Bank Secrecy Act (BSA), the Anti-Money Laundering Act of 2020 (AML), and countering the financing of terrorism (CFT) policy for decades. We also have experience with international AML matters, including in the EU and with respect to Financial Actions Task Force (FATF) recommendations....Read more

Industry

Artificial Intelligence (AI)

Experience 165 results

Experience

|

October 27, 2025

Winston Advised GenNx360 Capital Partners in its sale of Aero 3, Inc.

A Winston team led by Justin Levy and Eric Kaufman represented GenNx360 Capital Partners, a New York-based private equity firm investing in industrial and service companies, in connection with the sale of Aero 3, Inc. to VSE Corporation (NASDAQ: VSEC), a leading provider of aviation aftermarket distribution and repair services.  Headquartered in Manchester, New Hampshire, Aero 3 is a diversified global Maintenance, Repair and Overhaul (MRO) service provider and distributor supporting the commercial wheel and brake aftermarket. This transaction builds on GenNx360’s successful buy-and-build strategy....Read more

Experience

|

October 1, 2025

AA Mission Acquisition Corp. II - Initial Public Offering

Winston & Strawn LLP represented AA Mission Acquisition Corp. II, a blank check company, in the recent closing of its $100 million Initial Public Offering (IPO). The offering consisted of 10,000,000 units priced at $10.00 per unit, before deducting underwriting discounts and estimated offering expenses. The units began trading on the New York Stock Exchange (NYSE) under the ticker symbol “YCY.U” on October 1, 2025....Read more

Experience

|

September 29, 2025

Winston Advises PJT Partners in Beyond Meat’s $1.105 Billion Exchange Offer

Winston & Strawn LLP represented PJT Partners in its role as dealer manager to Beyond Meat, Inc., a publicly traded food technology company and leading producer of plant-based meat alternatives, in connection with an exchange offer and consent solicitation for any and all of its $1.105 billion of 0% Convertible Senior Notes due 2027 for up to $202.5 million in new 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030 and up to approximately 326 million shares of common stock....Read more
View All Experience

Insights & News 5,869 results

Article

|

November 21, 2025

|

3 Min Read

The Human Touch Lawyers Need to Succeed in an AI-Driven World

This article was originally published in Bloomberg Law. Reprinted with permission. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only. This article was co-authored with PrincetonComms founder Matt Eventoff. ...Read more

Benefits Blast

|

November 20, 2025

|

10+ Min Read

2026 Proxy Season: A Look Ahead to Executive Compensation Issues and Considerations

As the 2026 proxy season approaches, companies should be mindful of developments in required executive compensation disclosures and related issues that may arise as they prepare proxy statements. This alert surveys key developments and provides specific action items for companies to consider.

Winston’s Environmental Law Update

|

November 19, 2025

|

4 Min Read

Companies Need to Know These Key Exemptions in EPA’s Proposed Revision to the PFAS Reporting Rule

On November 10, 2025, the Environmental Protection Agency (EPA or the Agency) issued a proposed rule to revise the reporting and recordkeeping requirements for per- and polyfluoroalkyl substances (PFAS) under Section 8(a)(7) of the Toxic Substances Control Act (TSCA).

View All Insights & News

Other Results 88 results

Law Glossary

What Is the Standard for the FDA to Grant a Generic Drug License?

An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug....Read more

Law Glossary

What Is the Approval Process for Generic Drugs?

Approval for generic drugs are governed by the Hatch-Waxman Act. The Hatch-Waxman Act provides the framework for an applicant to demonstrate that its proposed generic product is bioequivalent to the brand-name drug....Read more

Law Glossary

What Is a Generic Drug?

Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising